ART exerted its anticancer effects by inducing ROS production and DNA oxidative damage, thus activating the p53/Cdk4/6-p16-Rb cell cycle checkpoint control pathways in ESCC cells. The gene discussed is CDKN2A; the disease is esophageal squamous cell carcinoma.